Timing note: Align reports today, Wednesday, July 29, 2026, after the market close—not tomorrow. Results are scheduled for 4:00 p.m. ET, followed by the earnings call at 4:30 p.m. ET.
The central question into 2Q is not whether Align can produce reported revenue growth; its own guide already calls for it. The more important questions are:
The setup is reasonably constructive operationally. Align entered the quarter with record 1Q shipments, international double-digit growth, growing DSO adoption, improving manufacturing productivity, and a product mix that is designed to lower doctors’ upfront cost while lifting Align’s gross-margin profile. The offset is that the U.S. retail channel remains soft and elective-treatment demand is still sensitive to consumer confidence, financing availability, and patient conversion.
| Metric | 2Q26 guide | Context |
|---|---|---|
| Total revenue | $1.04B–$1.06B | Midpoint of $1.05B, approximately +3.7% YoY and +1.0% QoQ |
| Clear Aligner shipments | Up QoQ and YoY | Implies shipments above 1Q26’s record 685.7k cases |
| Clear Aligner ASP | Flat QoQ and YoY | Mix and pricing discipline matter as much as volume |
| Systems & Services revenue | Up QoQ | Seasonal rebound in scanners/services is expected |
| GAAP operating margin | ~16.4% | Up from 13.6% in 1Q26; roughly 30 bps above 2Q25 |
| Non-GAAP operating margin | ~21.5% | Flat sequentially despite expected volume and Systems recovery |
At the revenue midpoint, the 16.4% GAAP operating-margin guide implies about $172 million of GAAP operating income; the 21.5% non-GAAP guide implies about $226 million. The margin delivery, and any change to the full-year outlook, should therefore be highly consequential.
Management guided Clear Aligner volume up both sequentially and year over year. Since 1Q26 shipments were 685.7k cases and 2Q25 shipments were 644.4k, the sequential comparison is the harder hurdle: 2Q26 should exceed 685.7k cases. That would also equate to at least roughly 6.4% YoY shipment growth.
At its June investor conference, management described normal 1Q-to-2Q seasonality as more than 3% sequential revenue growth, helped by a scanner rebound and the beginning of orthodontic seasonality. Yet the issued 2Q revenue midpoint contemplated only about 1% sequential growth, explicitly reflecting caution around geopolitical and macro uncertainty.
That framing creates potential upside if normal seasonality, international growth, and scanner demand played out better than the conservative assumptions.
In 1Q, Clear Aligner volume grew double digits in EMEA, APAC, and Latin America. Management indicated international markets represent about 55% of the company’s business, and China continued to grow double digits despite an intensely competitive environment.
For 2Q, investors should focus on whether those regions again offset weak North American retail demand. Strong international growth is valuable, but it can pressure consolidated ASP because emerging-market list prices are generally lower.
DSOs represented roughly one-quarter of global Clear Aligner volume in 1Q and delivered double-digit volume growth across regions. In the U.S., Align’s financing initiatives—especially Healthcare Finance Direct—are intended to improve conversion by enabling patients to prequalify and by reducing front-office friction.
The bull case is that Align can increasingly replicate DSO best practices in independent practices: more scans, better treatment visualization, better financing access, and a more systematic patient-conversion process.
Management is expanding configurations with limited or no included additional aligners/refinements, including its Zero Additional Aligner offering. These products reduce upfront cost for doctors and can help Align compete against wires-and-brackets treatment or lower-priced competitors.
Economically, the products can be attractive for Align because they require less manufacturing and carry less deferred-revenue burden. In 1Q, management specifically cited lower refinement rates, higher throughput, operational efficiency, and favorable product mix as contributors to gross-margin expansion.
Align characterized North American case volumes as modestly down year over year in 1Q, while international markets delivered much stronger growth. Management has attributed the weakness principally to macro conditions and less patient traffic/conversion, rather than a material change in competition.
That distinction will be tested in 2Q. If U.S. retail case starts remain weak—or worsen—it could revive concerns that consumer elective demand, financing friction, or down-trading to braces are limiting domestic growth.
Align expects 2Q ASP to be flat sequentially and year over year, but the components remain mixed:
Management’s broader 2026 outlook still assumed a 1%–2% annual ASP decline. Thus, a stable 2Q ASP would be encouraging, but investors will want to understand whether second-half ASP pressure remains embedded in the full-year framework.
1Q Systems & Services revenue was $184.1 million, down 12.1% sequentially due to normal first-quarter capital-equipment seasonality. Management guided this segment up sequentially in 2Q.
The segment needs to demonstrate that iTero Lumina adoption, services, exocad, and scanner placements can sustain growth even as the company offers more lower-priced, PC-based, leased, and rental configurations. A sequential recovery below expectations would hurt the total revenue result and potentially signal continued equipment-budget caution among practices.
Even if 2Q beats, management may elect to retain its 2026 outlook because it has emphasized uncertainty around consumer demand, patient traffic, fuel/freight costs, currency, tariffs, and the broader geopolitical environment.
That would not necessarily mean the operating trend deteriorated. But for the stock, a beat accompanied by unchanged full-year guidance could be interpreted less positively than a beat with clearer confidence in the back half.
How did North American retail volumes trend through the quarter, and did patient financing improve conversion?
This is the most important read-through on domestic discretionary demand.
Was the conservative 2Q guide exceeded because conditions improved, or simply because the initial guide had a large buffer?
The answer affects confidence in the second-half outlook.
How much of growth came from volume, price, FX, product mix, and deferral timing?
Investors should distinguish underlying demand from reported-revenue mechanics.
What is the current outlook for ASP in the second half?
The 2026 guide contemplates a modest annual ASP decline despite expected flat 2Q performance.
Are Zero Additional Aligner configurations producing incremental cases, taking share from braces, or mostly shifting existing case mix?
Incrementality matters more than simply better per-case margin.
What are the latest trends in China, EMEA, and Latin America?
International has carried the growth narrative and needs to remain resilient.
Does management still view full-year margin expansion as achievable without relying on a material macro improvement?
This determines whether the 2026 earnings algorithm remains intact.
ALGN closed at $175.63 on July 28, up about 12.6% year to date, but roughly 1.6% below its April 29 close—the day of the 1Q26 report. That suggests the market has not fully rewarded the favorable 1Q operational momentum and remains focused on the durability of U.S. demand, mix/ASP, and the credibility of the 2026 margin ramp.
A constructive result would feature:
The principal downside scenario is a quarter in which international growth remains solid but is insufficient to offset weak U.S. retail demand, lower-than-expected scanner revenue, or ASP/mix pressure—forcing management to preserve a cautious full-year posture.
For investors, case volume, North American retail commentary, ASP, and the full-year margin framework should matter more than a modest headline revenue beat or miss.